Author: George Underwood

Overall revenues were at $4.7 billion, down 18% from the prior year period

Only 14% of MPs and 16% of MEPs believe the sector takes priority in negotiations, but both want a greater understanding of pharma’s needs

Next phase of business continuity plan will launch 1 October at the latest as Agency faces higher-than-expected staff losses

Aegerion Pharmaceuticals Myalepta approved by EC

Drug becomes the first oral therapy and Janus kinase (JAK) inhibitor available for UC